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Objective—Trauma histories and symptoms of PTSD occur at very high rates in people with 
HIV and are associated with poor disease management and accelerated disease progression. The 
authors of this study examined the efficacy of a brief written trauma disclosure intervention on 
posttraumatic stress, depression, HIV-related physical symptoms, and biological markers of HIV 
disease progression.
Method—HIV-infected men and women were randomized to four 30-min expressive writing 
sessions in either a treatment (trauma writing) or an attention control (daily events writing) 
condition. The disclosure intervention augmented the traditional emotional disclosure paradigm 
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with probes to increase processing by focusing on trauma appraisals, self-worth, and problem 
solving. Outcomes were assessed at baseline, 1-, 6-, and 12-month follow-up.
Results—Hierarchical linear modeling (N = 244, intent-to-treat analyses) revealed no significant 
treatment effects for the group as a whole. Gender by treatment group interactions were significant 
such that women in the trauma-writing group had significantly reduced posttraumatic stress 
disorder (PTSD) symptoms (p = .017), depression (p = .009), and HIV-related symptoms (p = .
022) compared with their controls. In contrast, men in the trauma-treatment condition did not 
improve more than controls on any outcome variables. Unexpectedly, men in the daily-event-
writing control group had significantly greater reductions in depression then men in the trauma-
writing group. Treatment effects were magnified in women when the analysis was restricted to 
those with elevated PTSD symptoms at baseline.
Conclusions—A brief (4-session) guided written emotional disclosure intervention resulted in 
significant and meaningful reductions in PTSD, depression, and physical symptoms for women 
with HIV, but not for men.
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The prevalence of traumatic and stressful life events among people with HIV is alarmingly 
high, and there is a large body of research documenting the deleterious effects of trauma on 
health behaviors, health status, and disease progression. People living with HIV report high 
rates of sexual and physical abuse (>50%, Whetten et al., 2006), other life stresses and 
traumas (>90%, Pence et al., 2007; 61%; Gore-Felton, Butler, & Koopman, 2001), and 
posttraumatic stress disorder (PTSD; 61%; Gore-Felton et al., 2001; Kimerling, Calhoun, et 
al., 1999; Leserman et al., 2005; Whetten et al., 2006; Whetten, Reif, Whetten, & Murphy-
McMillan, 2008). Rates of trauma are high for both sexes. They are, however, particularly 
elevated in HIV-infected women: 55% of women versus 38% of men met criteria for acute 
stress disorder (Israelski et al., 2007), and 68% of women versus 35% of men report having 
experienced sexual assault (Kalichman, Sikkema, DiFonzo, Luke, & Austin, 2002).
Previous research has documented the detrimental impact of trauma, stress, depression, and 
PTSD on immune changes, physical functioning, and disease progression in HIV infection 
(Burack et al., 1993; Chida & Vedhara, 2009; Leserman, 2008; Leserman et al., 2002, 2005, 
2007; Ickovics et al., 2001; Ironson et al., 2005; Kemeny & Dean, 1995; Kemeny, Weiner, 
Duran, & Taylor, 1995; Kimerling, Armistead, & Forehand, 1999; Mayne, Vittinghoff, 
Chesney, Barrett, & Coates, 1996; O’Cleirigh, Skeer, Mayer, & Safren, 2009). In addition, 
stress and trauma have been associated with adverse health behaviors that hinder the 
management of HIV such as low adherence (Leserman, Ironson, O’Cleirigh, Fordiani, & 
Balbin, 2008) and high risk behaviors (Reisner, Mimiaga, Safren, & Mayer, 2009). Studies 
have also shown that coping with stress and trauma by means of avoidance and denial may 
lead to immune decrements and faster HIV disease progression (Chida & Vedhara, 2009; 
Ironson et al., 1994, 2005; Leserman et al., 2002; Moskowitz, Hult, Bussolari, & Acree, 
2009; Temoshok, Wald, Synowski, & Garzino-Demo, 2008). Thus, a substantial number of 
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studies support the notion that trauma and denial or repression of emotion may have 
deleterious effects on the health status of patients with HIV.
The health and psychological benefits of brief expressive writing (EW) interventions have 
been the focus of many studies, with generally positive results (see comprehensive review of 
146 studies in Frattaroli, 2006). More specifically, emotional disclosure studies have shown 
that writing about trauma, compared with writing about trivial events, has salutary health 
effects in reducing physical symptom reports and health center visits, depression, and pain, 
and in improving physical functioning (Frisina, Borod, & Lepore, 2004; Gidron et al., 2002; 
Pennebaker & Beall, 1986; Pennebaker & Susman, 1988; Richards, Beal, Seagal, & 
Pennebaker, 2000; Smyth, 1998; Smyth, Stone, Hurewitz, & Kaell, 1999). Meta-analyses of 
trauma writing have shown variable effects on psychological status ranging from no effect 
(Frisina et al., 2004; nine studies) to moderate effects (Frattaroli, 2006; 146 studies) to large 
effects (d = 0.66; Smyth, 1998; 13 studies).
However, most of the studies comprising these meta-analyses were conducted in healthy 
student samples; few focused on the medically ill. Interestingly, a meta-analysis of nine 
emotional-disclosure interventions limited to nonstudent clinical samples (e.g., asthma, 
arthritis, cancer) showed that expressive writing was more effective in improving physical 
health than psychological well-being (Frisina et al., 2004). On the other hand, Harris (2006) 
reported that writing about stressful experiences was associated with fewer health care visits 
only in the healthy samples (13 studies), not in medically ill samples (9 studies) or 
psychologically stressed samples (10 studies). In the few studies of the individuals with 
medical illnesses in which physical symptoms were included as an outcome variable 
(Willmott, Harris, Gellaitry, Cooper, & Horne, 2011, who studied 179 myocardial infarction 
patients; Smyth, Stone, et al., 1999, who studied 112 patients with asthma and rheumatoid 
arthritis; Broderick, Junghaenel, & Schwartz, 2005, who studied 92 fibromyalgia patients; 
Stanton et al., 2002, who studied 60 women with breast cancer; and Rosenberg et al., 2002, 
who studied 30 men with prostate cancer), a therapeutic effect was found with effect sizes 
(d) ranging from 0.42 to 0.62 (Broderick et al., 2005; Frisina et al., 2004; Willmott et al., 
2011). Modest effects of EW have been found on pain in patients with rheumatoid arthritis 
(Lumley et al., 2011) and with cancer, but only in those with high emotional disclosure 
(Cepeda et al., 2008). Some studies have found no effect of EW on physical symptoms; of 
note, Harris, Thoresen, Humphreys, and Faul (2005) failed to replicate the Smyth et al. 
(1999) findings in 137 asthma patients; Low, Stanton, Bower, and Gyllenhammer (2010) 
failed to find an effect in 62 metastatic breast cancer patients; and van Middendorp, Geenen, 
Sorbi, van Dooren, and Bijlsma (2009) failed to find an effect in 68 rheumatoid arthritis 
patients. Gillis, Lumley, Mosley-Williams, Leisen, and Roehrs (2006) found delayed (to 3-
month follow-up) benefits of limited clinical significance in 83 fibromyalgia patients. In one 
study of 50 adolescents with asthma, Warner et al. (2006) found an effect on physical 
symptoms only when the analysis was restricted to those above the median. Nonetheless, the 
preponderance of findings suggests that EW is associated with fewer reported physical 
symptoms, warranting a trial in patients with HIV.
The effect of emotional disclosure through writing in HIV-infected samples has been 
evaluated in only a few studies of randomized controlled trials (RCTs). Petrie, Fontanilla, 
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Thomas, Booth, and Pennebaker (2004) found a significant protective effect of trauma 
writing on CD4 + lymphocyte counts but not viral load (VL) with a sample of 37 people 
with HIV. Rivkin, Gustafson, Weingarten, and Chin (2006) studied a writing intervention 
focused on living with HIV (rather than trauma) and reported no effect on depression or on 
beta 2 microglobulin in 79 people with HIV but did not measure CD4 counts, VL, or trauma 
symptoms. Wagner, Hilker, Hepworth, and Wallston (2010) found no effects of trauma 
writing (vs. trivial writing control) on psychological outcomes, pain, or physical functioning 
in 37 people with HIV. Wyatt et al. (2004) used trauma writing as part of her integrated risk 
reduction/prevention intervention in people with HIV and found a positive impact on sexual 
risk reduction and adherence to medications in those who attended more sessions. Of 
interest, none of these studies included PTSD symptoms or physical symptoms as outcomes.
Only a few studies have examined the effect of EW on PTSD symptoms; some selected for 
PTSD and others did not. In the largest RCT of EW in people with PTSD (150 women who 
had been raped), Resick et al. (2008) found a significant improvement in PTSD symptoms 
and depression. Three smaller studies of people with PTSD—Sloan, Marx, and Greenberg’s 
(2011) study of 42 undergraduates; Smyth, Hockemeyer, and Tulloch’s (2008) study of 25 
people from a Veterans Administration or rape crisis center; and Bugg, Turpin, Mason, and 
Scholes’ (2009) of 67 traumatic injury patients (with elevated acute stress disorder)—
showed no effect of EW on PTSD symptoms between intervention and control groups, 
although the Smyth et al. (2008) study did find improvement in mood and posttraumatic 
cognitions. Studies in which there was no selection for PTSD diagnosis but in which PTSD 
symptoms were measured as an outcome variable have also had mixed results, with Sloan 
and Marx (2004) finding a significant decrease in PTSD symptoms, depression, and physical 
symptoms in 49 undergraduate students, and Schoutrop, Lange, Hanewald, Davidovich, and 
Salomon (2002) finding a significant effect on intrusion, avoidance, and depressive 
symptoms, whereas Gidron, Peri, Connolly, and Shalev (1996) found no beneficial effect in 
14 trauma victims. Thus, the literature is mixed with respect to effects of EW on PTSD 
symptoms.
A few other (nonintervention) studies in HIV bear on the issues of emotional expression and 
emotional–cognitive processing and health in HIV. In a study of 80 HIV-positive gay men, 
Cole, Kemeny, Taylor, and Visscher (1996) found that those who concealed their 
homosexuality had faster disease progression. After controlling for health behaviors, 
demographics, and treatment regimen, Eisenberger, Kemeny, and Wyatt (2003) found that 
higher inhibition words were associated with lower CD4 counts. These studies support a 
theoretical rationale that inhibition may be a pathway to poorer health. In addition, our own 
preliminary work in this area has linked processing of reappraisals, self-esteem, and coping 
efficacy within the context of written emotional disclosure of stressful experiences to 
symptom-free and long-term survival in patients with HIV/AIDS (O’Cleirigh et al., 2003; 
O’Cleirigh, Ironson, Fletcher, & Schneiderman, 2008). This work has also has shown that 
emotional processing is a better predictor of disease progression over 1 year, improved 
immune status (CD4 and natural killer [NK] cells), and better health behaviors than 
emotional disclosure alone (O’Cleirigh et al., 2002). As this work suggested that emotional–
cognitive processing of trauma (in addition to emotional disclosure) was protective of health 
in individuals with HIV, the disclosure intervention was augmented to stimulate emotional–
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cognitive processing in particular areas. Specifically, as part of each of the written disclosure 
tasks, patients wrote about their understanding or appraisal of the traumatic situation, 
feelings of self-worth and self-esteem, and coping or problem-solving efforts in response to 
the trauma. We view this augmented trauma-writing intervention as theoretically consistent 
with other empirically supported treatments for PTSD such as cognitive processing therapy 
(Resick & Schnicke, 1992; 1996) and prolonged exposure (Foa & Kozak, 1986), whose key 
elements are cognitive restructuring and exposure. This augmented brief written disclosure 
intervention also is theoretically consistent with conceptualizations of the necessary 
conditions for therapeutic resolution of stressful experiences (i.e., overcoming recurring 
patterns of avoidance and rumination through exposure to distressing memories and 
subsequent emotional processing; Foa & Kozak, 1986; Horowitz, 1986).
In summary, there is enough evidence suggesting that an emotional disclosure intervention 
might have a beneficial effect on both psychological and physical health in patients with 
HIV to warrant an RCT. We hypothesized that those writing about trauma would have 




Our study sample was recruited from HIV-infected men and women in south Florida 
(Miami–Dade and Broward County) from February 2004 through January 2009 (with 
follow-up assessments through February 2010). Research participants were recruited from 
community organizations (e.g., positive connections), doctors’ offices, family health clinics 
in minority neighborhoods, relevant events (AIDS walk, gay pride), gay gathering places 
(bars, bookstores, and so forth), newspaper and newsletter advertisements, and word of 
mouth. As indicated in the consort statement flow chart (Figure 1), we screened 1,128 HIV 
infected men and women for inclusion/exclusion criteria, 264 were enrolled and underwent 
baseline assessment, and 244 were randomized (121 to the intervention and 123 to the 
control group). Randomization was stratified on gender, education (high school education or 
less vs. more education), and use of highly active antiretroviral therapy (HAART) to ensure 
that the treatment and control groups were equivalent on these variables. Of those 
randomized, 10.7% (13/121 in treatment, 13/123 in control) were lost to contact (or 
withdrew, n = 4 included in that figure) between baseline and 1-month follow-up (F1), 
another 6.1% were lost to contact (or withdrew, n = 3) between F1 and 6-month follow-up 
(F6; 5/105 treatment and 8/109 control), and 6.8% were lost between F6 and 12-month 
follow-up (F12). The overall dropout rate (lost to contact or withdrew) to 12 months was 
thus 22.3% (27/121) in the treatment group and 20.3% (25/123) in the control group. (We 
did not include those who were deceased or incarcerated or had moved in this calculation). 
Although these rates may be considered high, note that this is a low socioeconomic status 
(SES) group often without the resources to have a stable home or cell phone. Dropout rates 
did not differ between groups.
Ironson et al. Page 5













Inclusion and Exclusion Criteria
We recruited HIV-positive people in the mid-range of illness. We wanted to eliminate 
patients who had little room for improvement (CD4 >600) or whose disease progression 
(CD4 <100) would likely overshadow a trauma reduction treatment (when retested by our 
labs, 85% fell into a CD4 range of 100–600). We included those with one Category C 
symptom (AIDS defining) historically but excluded those with C symptoms in the year prior 
to entering the study. Although subjects were part of a stress or trauma treatment study 
(writing about stress or trauma), we assumed the stress of HIV was sufficient to enter the 
study and did not require the presence of additional trauma. Other exclusion criteria 
included those younger than 18 and older than 70 years; those who were illiterate or could 
not write at an eighth-grade level, confirmed by the Test of Written Language (3rd ed.; 
Hammill & Larsen, 1996); those with active systemic diseases or disorders that would 
interfere with participation or confound prediction of disease progression (e.g., heart, lung, 
kidney, liver, cancer, or stroke); those with current alcohol or substance dependence or 
psychotic symptoms (confirmed by the appropriate Structured Clinical Interview for DSM–
IV module (First, Spitzer, Gibbon, & Williams, 1997); those who were planning to change 
HIV medications within 6 months or who had changed HIV medications in the previous 3 
months; those initiating use of antidepressant medication during the month before the study; 
those had undergone surgery with general anesthesia in the previous 3 months; and those 
who could not commit to four treatment sessions.
Procedures
The institutional review board at the University of Miami approved the study, and all 
patients signed an informed consent at the beginning of their initial screening visit 
(baseline). Blood was drawn, and questionnaires and interviews were administered at the 
baseline visit. Participants returned for the first study visit (N = 244) where they were 
randomized to either the augmented trauma-writing intervention or the daily-event-writing 
control. Both experimental and control participants were asked to visit the study on four 
occasions during a 2- to 4-week period so that they could write for 30 min in a private 
office. After each writing session, the writings were submitted to the researchers. 
Questionnaires, interviews, and blood draws again were administered at 1, 6, and 12 months 
after the end of the writing intervention.
Experimental condition (augmented trauma-writing) instructions—During the 4 
writing days, participants were asked to write about the most traumatic or upsetting 
experiences of their entire life. In their writing, they were asked to “really let go” and 
explore their “very deepest emotions and thoughts.” Subjects were told that it was best to 
write about a major trauma and encouraged to write about the same experience on all 4 days. 
However, they were told it was okay if they wrote about current conflicts. Subjects were 
encouraged to write about traumas or conflicts they had not discussed in great detail with 
others. They were told to write continuously for 20 min. These instructions were based upon 
those used in previous studies (Kelley, Lumley, & Leisen, 1997; Pennebaker, Barger, & 
Tiebout, 1989; Pennebaker & Beall, 1986). When the 20-min writing session was 
completed, subjects were asked to write for an additional 10 min and given the following 
instructions (processing probes) for each session, respectively—Session 1: How you have 
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tried to understand and make sense of the traumatic experience(s)?; Session 2: How does the 
traumatic experience affect your feelings about yourself, your self-worth, and your self-
esteem?; Session 3: How does the traumatic experience affect your ability to solve 
problems, to meet future challenges, or to deal with day-to-day stress?; and Session 4: How 
have you tried to understand the trauma and make sense of it?
Control condition (daily-event-writing) instructions—Those in the control condition 
were asked to write a description about what they did “yesterday from the time [they] got up 
until the time [they] went to bed” for 20 min continuously. They were told to “avoid writing 
about [their] emotions or opinions” but to try to be as “accurate and objective as possible.” 
The 20-min writing period was followed by 10 more min of describing in writing what they 
had done “today from the time [they] woke in the morning.” These instructions were 
modified slightly for three subsequent writing sessions to reflect descriptions of what they 
did on different days or what they planned to do on future days.
Measurement
HIV disease progression and health measures
CD4 counts: Flow cytometry was performed in one lab to enumerate CD3 + CD4 
lymphocytes with fluorochrome conjugated monoclonal antibodies in a four-color system.
Viral load (VL): HIV-1 VL was performed with the Roche Amplicor RT/PCR assay 
(Roche Molecular Diagnostics, Pleasanton, CA), which measures down to 400 copies of 
HIV RNA in plasma.
HIV symptom checklist: Experimenters assessed symptoms relevant to HIV (based on the 
Centers for Disease Control and Prevention criteria for Category B symptoms) by interview 
using an HIV symptom checklist. Symptoms were assessed for the previous month at 
baseline and the 1 month visit, and for the previous 6 months, at the 6-month and 12-month 
visits; thus, symptoms were assessed during the whole follow-up period. Examples of 
symptoms are herpes zoster (shingles), oral thrush, cervical dysplasia, pelvic inflammatory 
disease, low platelet count (<50,000), peripheral neuropathy, chronic unexplained fever, and 
chronic unexplained diarrhea.
Psychosocial/distress assessment measures
Davidson PTSD Scale (PTSDTOT; Davidson et al., 1997; Zlotnick, Davidson, Shea, & 
Pearlstein, 1996): This scale is a 17-item interview-administered measure based on the 
PTSD symptom clusters defined by Diagnostic and Statistical Manual of Mental Disorders 
(4th ed.; American Psychiatric Association, 1994). Each item is rated from 0 to 4 for both 
frequency and severity during the past week. Items are summed for a total score, and 
subscales measure re-experiencing, avoidance, and arousal. The total scale has demonstrated 
good test–retest reliability (r = .86) and internal consistency (r = .99). In diagnosing PTSD 
compared with the SCID, the positive predictive value was 92% and the negative predictive 
value was 79%, with a cutoff score of 40 for PTSD suggested by Davidson (1996).
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Hamilton Depression Scale (HAM–D): This 17-item interview-based measure is 
considered the gold standard for assessing severity of depression (Hamilton, 1967). Our 
team has found high interrater reliability with intraclass correlation coefficient of .95. Our 
assessments for the Hamilton and Davidson PTSD scales were done by interviewers who 
were blind to group assessment, except in a few rare cases.
Manipulation check: Adherence to probes: Essays were scored from the first writing 
session to determine whether people were paying attention to the directions (e.g., to ensure 
that the daily-writing group was not writing about trauma and that the trauma-condition 
group wrote about trauma and attended to the probe question). In all cases, directions were 
followed.
Statistical Analysis
Hierarchical linear models (HLM) were used to evaluate study outcomes. Because HLM 
uses all randomized participants, these are intent-to-treat analyses. We conducted analyses 
on HLM Version 6.06 software (Raudenbush, Bryk, Cheong, Congdon, & du Toit, 2004). 
Level-1 and Level-2 data sets were prepared with SPSS Version 17.0. The Level-1 model 
includes only the time variable, which provides the structure of the analysis and captures 
within-person change over time. The time structure, months since baseline, was held 
constant within-subject and was based upon the mean number of months since baseline for 
each assessment time point. In the Level-2 model, between-person characteristics, such as 
treatment condition, gender, and their interaction, are used to predict the slope estimates 
representing change in the dependent variables. For the Level-2 models, the baseline value 
of the dependent variable was included as a covariate to ensure that individual variation at 
study entry was controlled in the calculation of the slope estimates. HIV symptoms were 
dichotomous, and they were modeled using a Bernoulli distribution with a correction for 
overdispersion. For all HLM models, continuous measures in the Level-2 model were 
centered around their group means, and all dichotomous variables were coded 1/0 to allow 
for more meaningful evaluation of parameter estimates. For model parameters, we used 
restricted maximum-likelihood estimation with robust standard errors. We tested 
unconstrained models to confirm significant individual variation about the slope and 
intercept before accounting for random assignment. Treatment effects were evaluated by an 
examination of the significance of the gamma coefficient associated with treatment 
condition in the Level-2 model. Gamma (γ) represents the change in the slope over time of 
the dependent variable of interest (for example, PTSD symptoms) predicted from the 
independent variable of interest (in this case, group assignment), with any other variables in 
the Level-2 model (in this case, baseline PTSD symptoms) controlled. Follow-up analyses 
of the gender-moderated effects were examined with models that included group treatment 
condition, gender, baseline value of the outcome, and the group by gender interaction in the 
Level-2 model. For analyses involving VL, we used the log transformation; however, means 
are presented using actual values. Comparisons between treatment conditions on 
demographic and disease-related variables were done with t tests (for continuous variables) 
and chi-square tests (for categorical variables). We calculated effect sizes (Cohen’s d) for 
pre–post using the mean difference divided by the standard deviation (SD) of the 
differences. Effect size for between-group change (pre–post trauma writing vs. pre–post 
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control writing) is the mean pre-to-post difference in the trauma-writing group minus the 
mean pre-to-post difference in the daily-events-writing group divided by the weighted 
average of the SD of the difference scores within the trauma-writing group and SD of the 
difference scores within the daily-events-writing group.
Results
There were 244 research participants randomly assigned to the treatment (N = 121) or 
control (N = 123) groups. The average age of the sample was 42.8 years old (SD = 8.8). The 
sample was ethnically and racially diverse with more than half the sample (56%) identifying 
as African American or Afro Caribbean. Whites and Hispanics were similarly represented 
with each group accounting for slightly less than 20% of the sample (17% and 19.5%, 
respectively). Women composed about 40% (39.3% = 96/244) of the sample, and 42.6% of 
the entire sample identified as gay or bisexual. About 30% of the sample had not graduated 
from high school, although nearly half of the sample had educational experiences beyond 
high school (43% had some college or trade school, and 5.4% were college graduates). The 
only demographic variable that differed significantly between experimental and control 
groups was the age difference, t(242) = 2.12, p = .035, with the controls being slightly 
younger (2.4 years). None of the other demographic variables differed significantly between 
the groups with all ps > .2. The mean CD4 cell number at study entry was 439 (SD = 235), 
and the mean number of HIV RNA viral copies in plasma was about 32,890 (SD = 98,869), 
which places the average study participant in the mid-range of HIV disease. Two thirds of 
the sample reported currently taking highly active antiretroviral medications. There were no 
significant differences between the groups on any of the disease characteristics.
Treatment Effects
The significance of the treatment effects were evaluated by examining the significance of 
the difference between the slopes (rate of change) of the study outcomes for the trauma-
writing and daily-writing-conditions from baseline through 1, 6, and 12 months 
postintervention (means and SDs are in Table 1 and the significance tests are in the first part 
of Table 2). None of the psychological or HIV disease progression markers differed between 
treatment conditions.
Gender-Moderated Effects
In the absence of significant main treatment effects, gender was examined as a moderator by 
testing gender by group interaction effects on the study outcomes using HLM as described 
in the Method section (second part of Table 2). In contrast to the main effects analyses, 
significant interaction effects for gender by condition were observed over time for PTSD 
symptoms, HAM–D, and HIV-related physical symptoms. Specifically, women receiving 
the trauma-writing treatment showed significantly greater reductions at follow-up in the 
severity of their PTSD symptoms, depression, and HIV-related physical symptoms than 
women in the control condition (tests in Table 3, Column A; descriptives in Table 4, 
Column A). Analyses of women alone (Table 3, Column A) show that the PTSD effect was 
driven by reductions in both avoidance and intrusions compared with controls’ levels of 
avoidance and intrusion. In men alone (Table 3, Column B & Table 4, Column B), with the 
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exception of HAM–D, there was no significant effect of group (group by time interaction) 
on any of the outcome measures. For depression, although both groups’ scores decreased 
over time, this reduction was only significant in the daily-writing group: daily γ = −1.36, 
t(72) = −3.91, p = .003; trauma γ = −.22, t(68) = −0.55, p = .581. For PTSD in the men, both 
trauma- and daily-event-writing groups experienced significant decreases over time; trauma 
γ = −3.27, t(69) = −2.17, p = .033; control γ = − 4.91, t(73) = −3.11, p = .003.
An examination of the gender-moderated effect on HIV-related physical symptoms was also 
significant (second part of Table 2). An examination of the means shows that women in the 
trauma-writing condition were significantly less likely to report HIV-related symptoms at 
follow-up than women in the control condition (Table 3, Column A & Table 4, Column A). 
For the men (Table 3, Column B & Table 4, Column B), there were no significant 
differences between treatment conditions in the likelihood of reporting HIV-related 
symptoms. There were no significant gender by group effects for CD4 or VL (Table 2).
Table 4 presents the means and SDs at baseline, 1-, 6-, and 12-month follow-up separately 
for women and men for each of the study outcomes that showed a significant group by 
gender interaction. An examination of the trends in the mean differences across treatment 
conditions reported for women and men elucidate the moderated effects and analyses 
reported in Tables 2 and 3. For women, but not men, the trauma writing was significantly 
associated with reductions in PTSD, depression, and HIV-related symptoms over time 
compared with controls.
Because the effects of trauma writing appeared to reduce PTSD symptoms in women, a post 
hoc examination of the subset of women for whom this reduction would be most clinically 
relevant (e.g., women with elevated PTSD symptoms [above the median of 20] at entry to 
the study) was conducted. This analysis would be justified only if PTSD symptoms at 
baseline moderated the relationship between group assignment and improvement (i.e., 
people with elevated PTSD improved more with the intervention). The group by baseline 
PTSD score interaction was significant in women, γ = .074, t(91) = 2.32, p = .023, so we 
proceeded to analyze the subset of women with elevated PTSD symptoms (PTSDTOT > = 
20). We chose the median rather than the PTSD cutoff to present in order to maximize the 
sample size and to include the subclinical as well as clinical range.1 Table 3, Column C, 
shows the results of the significance tests, and Table 5 shows the means and SDs across time 
for this subset of women on the clinically relevant variables. There was a significant effect 
of the intervention (group by time interaction) for PTSD symptoms (including significant 
reductions in avoidance, numbing, and hyper-arousal), depression, and HIV-related physical 
symptoms. Figure 2 shows the change in mean PTSD symptoms over time in each treatment 
condition for women with elevated PTSD at baseline (> = 20). The figure illustrates that 
there is a significantly greater reduction in PTSD symptoms in the trauma- versus the daily-
writing control group and that this reduction is maintained over time.
1A comparable test for women with PTSD scores at or above the diagnostic cutoff of 40 at baseline was performed and was 
significant as well. The group by time effect for PTSD symptoms: □ = 5.05, t(24) = 2.80, p = .01 Within the trauma group, the pre–
post effect sizes are 1.24 and 1.24 at 6 and 12 months, respectively. The between-group effect sizes are .67 and .58, respectively.
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The comparable tests for men with initial PTSD scores greater than 20 (n = 85) showed no 
significant effect of group (trauma-writing vs. daily-writing control) by time interactions for 
PTSD symptoms, γ = −1.74, t(82) = −1.51, p = .13), HAM–D (γ = −.55, t(80) = −1.60, p = .
11, or HIV symptoms, γ = .13, t(82) = 1.07, p = .29.
Effect sizes (Table 6) on PTSD symptoms for this most clinically relevant group (women 
with elevated PTSD symptoms at baseline) are large for pre-to-post changes in PTSD in the 
trauma-writing group (Cohen’s ds = 1.12 and 1.15 at 6 and 12 months, respectively). The 
parallel effect sizes for the group assignment interaction were more moderate (pre–post 
differences on PTSD in the trauma-writing vs. the control group: Cohen’s ds = 0.63 and 0.45 
at 6 and 12 months, respectively). All other effect sizes for outcomes of PTSD and 
depression are in Table 6 and are given for women only, men only, and the combined group.
Discussion
Within a large and diverse sample of HIV-positive men and women, no significant treatment 
effects were observed for any of the hypothesized study outcomes (depressive or PTSD 
symptoms, HIV-related symptoms, CD4 count, or HIV RNA viral load) for the group as a 
whole. However, there were significant gender by treatment group interaction effects. 
Among women only, the written trauma disclosure condition was associated with significant 
reductions in PTSD symptoms, symptoms of depression, and physical symptoms compared 
with a daily-events-writing control condition. Effects were even stronger for women with 
elevated PTSD symptoms at baseline. For men, an unexpected finding was that they had a 
greater decrease in depression in the daily-events-writing control condition than in the 
trauma-writing condition.
Our nonsignificant effects of trauma disclosure on PTSD symptoms are consistent with the 
findings of a number of studies of EW (Bugg et al., 2009; Sloan et al., 2011; Smyth et al., 
2008) while seeming to be inconsistent with others (Resick et al., 2008; Schoutrop et al., 
2002; Sloan & Marx, 2004), at least until gender is taken into account (see later discussion). 
Why would there be no significant effects of trauma writing on symptoms of PTSD and 
depression? From a cognitive–behavioral perspective, the primary theories of trauma 
resolution involve habituation through exposure (Foa & Kozak, 1986) or emotional–
cognitive processing, including restructuring of thoughts (Resick & Schnicke, 1992, 1996). 
The current intervention utilized the EW task, which is self-paced, and even with additional 
probes to increase emotional–cognitive processing, the task may not be as potent as having a 
therapist who can identify “stuck points” and work with the client to restructure thoughts, or 
who knows when to push for further exposure and when a person’s defenses may be 
overwhelmed. In addition, habituation is not likely to occur unless the fear structure is 
accessed and repeatedly exposed until anxiety subsides. These processes can be avoided in 
this self-controlled task. There is also no assigned homework, which in cognitive processing 
therapy involves identifying, challenging, and restructuring beliefs, or in exposure treatment 
involves a real-life in-vivo hierarchy of exposures. Given these considerations, as Lumley, 
Tojek, and Macklem (2002) noted, perhaps researchers should be looking for characteristics 
of people that identify who may benefit from expressive writing.
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This study suggests that gender may be one of these characteristics. Why would there be 
gender differences? The benefits of EW are thought to depend on the ability of people to 
access, express, process, and ultimately resolve negative emotional memories (Lumley et al., 
2002; Pennebaker, 1997). As hypothesized by Lumley et al. (2002), alexithymic people 
(who have deficits in emotional awareness and understanding) may derive less benefit from 
EW because they are less able to access and express emotions. To the extent that men may 
be more alexithymic than women, women may derive more benefit from EW. Other 
research has found that women are more emotionally expressive than men (Brody, 1997). 
Another moderator relevant to gender differences is the finding by Kraft, Lumley, D’Souza, 
and Dooley (2008) that patients with greater emotional approach coping (which may be 
more characteristic of women) derived more benefits from EW. In fact, Stanton, Kirk, 
Cameron, and Danoff-Burg (2000) showed that when students were dealing with a parent’s 
illness, matching the intervention with the student’s emotional approach tendency (for 
expressing emotions or receiving facts) was associated with better coping. It is possible that 
the men in our study may have used less emotional approach coping or may not have 
benefitted to the same extent as women from processing trauma. In addition, perhaps the 
additional instructions to augment emotional–cognitive processing in the trauma-writing 
condition may have interfered with men’s processing while enhancing women’s processing. 
In addition to differences in emotional awareness, expression, processing, and emotional 
approach coping, which may have affected PTSD recovery, several hypotheses may be 
raised regarding the lack of recovery of men from depression in the trauma-writing group 
compared with those in the daily-writing group: Perhaps the trauma writing was more 
upsetting for the men, making them more depressed, or perhaps the observation that the 
trauma was not resolved as well in men assigned to trauma writing may have been reflected 
in the lack of recovery from depression. Other possible reasons for the gender difference, 
which we intend to explore in future analyses, are that the women might be more engaged or 
involved in the writing task or that women write about different or more severe traumas. The 
latter is not likely since PTSD scores at baseline did not differ between men and women. It 
is also notable that the loss to follow-up for women was about half of the loss for men (see 
ns in Table 4). Finally, effects of life context and stigma may have played a role. Our 
women were predominantly African American (78%) and may have faced greater stigma 
from HIV in their community and have had less opportunity to safely disclose their status 
than the men, who were predominantly gay or bisexual (65%). Gay men can more easily 
seek out communities supportive of people with HIV.
How do our findings on gender differences compare with other emotional disclosure 
literature? In the largest meta-analysis to date, Frattaroli (2006) reviewed 146 emotional 
disclosure randomized studies and found no gender differences on mental or physical health 
outcomes. However, a large proportion of these studies (96/146 = 63.7%) were conducted 
on college student samples, often recruited from psychology classes. However, Frattaroli 
(2006) reported that studies with a higher proportion of men had a larger effect size (r = .
18). In his meta-analysis of 13 studies, Smyth (1999) also found that studies with a higher 
proportion of men had higher overall effect sizes, but the proportion of men was unrelated to 
psychological well-being or physiological functioning (p. 179) and gender effects were not 
directly tested. There are also theoretical reasons why men might be expected to gain more 
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from EW than women—because men are often socialized to inhibit emotional expression 
that makes them look weak or less masculine (Brody, 1996). Finally, it should be noted that 
the current study comprises a patient sample very different on key characteristics from the 
more typical samples reported in the emotional disclosure research: The two most 
predominant groups in our sample were African American women and gay men, and our 
sample was predominantly lower SES (mean annual income was $10,000) people. In 
addition, as noted, our writing task was augmented with specific directions designed to 
increase emotional–cognitive processing. It is plausible that men may not benefit from 
processing to the same extent as women, and therefore, the addition of probes in the current 
study may well have fostered gender differences.
Gender-Moderated Effects in Emotional Disclosure
Specifically, among all women in the trauma-writing group, PTSD symptoms decreased by 
38% and 35% at 6- and 12-month follow-ups, respectively. The effect sizes on PTSD 
symptoms among all women in the trauma treatment were modest (ds = 0.21 and 0.22 at 6 
and 12 months, respectively) compared with those in the control condition. However, when 
examining the women more at risk (those with PTSD at baseline >20), the reduction in 
PTSD symptoms was 50% at 6 months and 46% at 12 months, and the effect size on PTSD 
symptoms for trauma-writing women compared with the daily-writing controls was 
moderate (ds = 0.63 and 0.45, respectively) at 6 and 12 months. These interaction effect 
sizes are in the range of effect sizes reported for empirically supported treatments for PTSD, 
such as cognitive–behavioral therapy, prolonged exposure, and stress management among 
populations meeting PTSD criteria. Compared with the effect sizes in credible control 
groups (not waitlist or usual care), trauma-focused cognitive–behavioral therapy effects have 
been modest to large (ds = 0.27 to 1.01) in meta-analyses (Bisson & Andrew, 2005; Bradley, 
Greene, Russ, Durta, & Westen, 2005). The 46%–50% reduction in PTSD symptoms found 
for women with elevated PTSD symptoms is comparable to what has been found in some of 
the RCTs in which cognitive processing therapy has been used (12 sessions with rape 
victims, Resick, Nishith, Weaver, Astin, & Feuer, 2002; and 10 sessions with combat 
veterans, Monson et al., 2006), slightly less than what was found in Resick et al. (2008; five 
sessions with sexual abuse victims), and not as great as in others (Chard, 2005; 18 sessions 
with childhood sexual abuse victims).
As noted in the introduction, in addition to our study, only a few writing studies have 
included PTSD symptoms as an outcome. In view of our findings, it is instructive to review 
these studies with respect to gender and effect sizes. In a non-HIV sample of 150 adult 
women with PTSD, Resick et al.’s (2008) effect size (pre–post change) for writing about 
trauma was similar to what we found in women with PTSD (Davidson PTSDTOT >40) at 
baseline (d = 1.24 for our study at 6 and 12 months using pre–post change).2 Interestingly, 
Resick et al. (2008) found that writing about trauma was about as effective as the full 
cognitive processing therapy protocol (cognitive therapy including writing) at 6-month 
follow-up in reducing symptoms of depression and PTSD, although it was not as effective as 
2The estimation of pre–post effect size (ES) on PTSD symptoms from the Resick et al. (2008) study requires the estimation of a 
correlation between pre and post scores. Using r = .60 (the correlation in our data), her ES = 1.43; using a more conservative r = .50, 
her ES = 1.30. Note also that her study had five sessions of writing, whereas ours had four.
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the full protocol immediately posttreatment. A study of trauma writing by Sloan and Marx 
(2004) of 49 undergraduate women who experienced one or more traumatic stressors found 
a significant decrease in PTSD symptoms (ES = .43), depression (ES = .72), and physical 
symptoms (Pennebaker Inventory of Limbic Languidness; Pennebaker, 1982; ES = .49). 
Similarly, Schoutrop et al. (2002) found a significant effect of trauma writing on intrusions, 
avoidance, and depressive symptoms among 48 undergraduates (75% women) randomly 
assigned to write about a traumatic experience that still bothered them or to a wait list 
control. In contrast, the studies with mixed genders found weaker or no effects: Sloan et al. 
(2011) focused on 42 undergraduates with PTSD and found no effect on PTSD symptoms or 
depression. Gidron et al. (1996) studied 14 victims of motor vehicle accidents and found no 
beneficial effect of trauma writing. Similarly, Bugg et al. (2009) studied 67 trauma injury 
patients with acute stress disorder and found no effect of writing on anxiety, PTSD, or 
depression. Finally, one study of volunteers with PTSD (N = 25) from a Veterans 
Administration or rape and trauma center (11 males, 14 females) did not show an effect of 
EW on PTSD symptoms but did find improvements in mood and posttraumatic growth 
(Smyth et al., 2008). A later study of Gidron et al. (2007) also showed gender differences in 
a trauma recall intervention (not a writing study) of traffic accident victims—where a 
significant group by gender interaction revealed a reduction of PTSD symptoms for women 
but not for men. This literature, together with our results, suggests that writing about trauma 
may be particularly beneficial for reducing PTSD symptoms in women.
Another important clinical observation from the literature and from our study is that 
reductions in PTSD symptoms when writing about trauma (or, more broadly, exposure 
therapy or cognitive–behavioral therapy for trauma) appear to be accompanied by reduction 
in depressive symptoms as well. The reductions in symptoms of depression (HAM–D) in 
our study of 31% and 26% for all women at 6- and 12-month follow-ups, respectively, and 
of 56% and 40% for women with elevated PTSD at baseline are both statistically significant 
and clinically substantial. The effect sizes associated with these reductions in depressive 
symptoms (women with elevated PTSD symptoms: ds = 0.89 pretreatment/0.68 post-
treatment; and women with PTSD: ds = 0.91 intervention/0.47 controls) also are comparable 
to the findings for trauma-focused cognitive–behavioral therapy when compared with 
credible control groups (not waitlist or usual care), which have been modest to large (ds 
ranging from 0.28 to 1.08; Bisson & Andrew, 2005; Bradley et al., 2005). This suggests that 
treating PTSD may have the added benefit of reducing depression and raises the underlying 
question of whether the source of the depression may have been the trauma.
The impact of trauma writing on HIV-related physical symptom reports in women was also 
significant and substantial. In women writing about trauma, physical symptom reports 
decreased by 52% (means decreasing from 0.27 to 0.13), whereas in the control group, 
symptom reports increased by 20% (means increasing from .31 to .39) by the 6-month 
follow-up. At 12 months, the reduction in symptom reports was 22% (means decreasing 
from .27 to .21) in the trauma group compared with a 20% increase in the control group 
(means increasing from .31 to .39). These reductions in physical symptoms associated with 
trauma writing are similar to the reductions in psychological symptoms and add to the small 
Ironson et al. Page 14













but growing literature (noted in the introduction) suggesting that EW may have an impact on 
physical symptoms in the medically ill.
Finally, it is important to note that there were no effects on our objective measures of CD4 
and VL. While all effects that were found are subjective, note that assessment of outcomes 
through interview with an assessor blind to treatment should have minimized the 
subjectivity and that the control group had the same subjective measure bias.
Our findings also extend the literature on EW in HIV, since no other prior studies in HIV 
have included physical symptom reports or PTSD symptoms. It does contrast with the Petrie 
et al. (2004) study, which found an impact on CD4 cells; we did not find such an impact in 
ours but that study was smaller (n = 37) and the participants were mostly men (35/37). Our 
negative finding for the sample as a whole in alleviating depression is consistent with Rivkin 
et al. (2006). However, we did find effects for women, whereas they did not explore gender 
differences. Furthermore, their sample had few women (21 out of 79). Note also that their 
participants wrote about living with HIV, rather than trauma per se, and did not have the 
augmented processing probes.
Future Research
Research is needed in a larger sample of HIV-positive women with PTSD to determine 
whether the effects of writing will replicate. Determining who might benefit from this 
intervention, as was examined by Stanton et al. (2000, 2002) and Lumley et al. (2002), 
would be useful. It would also be useful to know how this brief, transportable intervention 
would compare with therapy. Research is also needed to determine if the findings regarding 
significant reduction in PTSD symptoms in women can be extended to other clinical 
populations with PTSD (not just HIV) and can extend to other HIV-relevant health-related 
outcomes such as sexual risk behavior or medication adherence. In addition, our unexpected 
findings in men of a significantly greater benefit of the daily-events-writing control group on 
depression need to be replicated. If the findings are replicated, this raises the question of 
whether a focus on daily activities may be more beneficial than a focus on processing the 
trauma for recovery from depression, at least in the context of a self-paced written task. 
Although writing about one’s worst trauma (emotional disclosure) has been tested among 
students and persons with chronic medical illness, it has not been placebo-controlled tested 
in a reasonably powered sample with sexual abuse histories or PTSD. Finally, we had a 
large number of exclusion criteria, and it would be useful to determine whether this brief 
writing intervention could be helpful to a wider clinical population.
Limitations of the Study
Although our study had a large sample size and used clinician-independent assessment for 
PTSD and depression, with established diagnostic cutoffs and not just self-reported current-
affect measures, there are several limitations. We did not test whether the processing probes 
added anything to the traditional written disclosure paradigm since we did not have a 
trauma-writing group that did not receive the probes. We screened out a large proportion of 
people who could potentially benefit from the intervention, (e.g., those with current 
substance dependence).
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This is the first study to show that the writing paradigm (by itself) has useful clinical effects 
(reduction in PTSD symptoms, depression, and HIV symptoms) in women with HIV. 
However it is important to note that we screened out anyone for whom a brief intervention 
might not be appropriate (mental instability, substance dependence, and so on). With our 
screening procedure in place, we found surprisingly few people (about 10%; 23 out of 244) 
who needed extra contact during the course of the study. We identified these people 
immediately after the writing sessions by elevated Subjective Units of Distress (SUDS; >80) 
or elevated Profile of Mood States (McNair, Lorr, & Droppleman, 1992) anger scores. These 
people were distributed evenly between the trauma-writing (n = 14) and daily-events-writing 
(n = 9) conditions, and thus, in most cases, the need for extra contact (mood checks with 5–
10 min of clinician-guided discussion) was not specifically related to the trauma writing. 
Thus, likely because EW is self-directed and self-paced, our data show it appears to be safe 
and involves no increased risk. Finally, there was no compelling data to suggest that men 
derived any clinical benefit from augmented trauma writing. In combination with previous 
literature, this finding suggests it is advisable to use the standard trauma-writing paradigm 
for men rather than trauma writing with the augmented probes used in this study.
Conclusion
A brief emotional disclosure treatment (writing about trauma augmented by probes to 
encourage processing) appears to significantly benefit women, but not men, in terms of 
reducing symptoms of PTSD, depression, and physical symptoms of HIV. Its potential for 
use as an adjunct treatment in women should be considered and investigated further.
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Study CONSORT flow chart, February 2004–February 2010. F1, F6, and F12 stand for 1-
month follow-up, 6-month follow-up, and 12-month follow-up, respectively.
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Posttraumatic stress disorder (PTSD) symptoms for trauma-writing versus daily-writing 
groups for women with elevated PTSD symptoms (above the median) on the Davidson 
PTSD Scale (PTSDTOT >20).
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Table 1
Means and Standard Deviations (in Parentheses) for Main Study Outcomes Across Baseline and 1-, 6-, and 
12-Month Follow-Ups
Outcome Baseline 1 month 6 month 12 month
PTSDTOT
 Treatment 27.69 (23.84) 20.63 (23.72) 17.66 (20.13) 18.08 (20.41)
 Control 28.65 (23.46) 23.84 (21.93) 19.83 (21.73) 17.89 (22.42)
HAM–D
 Treatment 9.61 (6.36) 8.41 (6.26) 8.13 (6.46) 7.54 (6.24)
 Control 10.32 (6.82) 8.99 (7.27) 8.30 (6.60) 7.09 (5.56)
HIV symptoms
 Treatment 0.25 (0.43) 0.24 (0.43) 0.19 (0.40) 0.22 (0.42)
 Control 0.21 (0.41) 0.25 (0.44) 0.27 (0.45) 0.26 (0.44)
CD4
 Treatment 410 (206) 421 (269) 419 (245) 429 (251)
 Control 467 (259) 466 (249) 464 (223) 491 (302)
Viral load
 Treatment 47,666 (126,768) 38,100 (100,172) 47,406 (114,877) 56,577 (142,846)
 Control 18,480 (57,401) 24,166 (79,005) 28,743 (94,105) 24,056 (68,682)
Sample sizea
 Treatment 120b 104d 94f 82h
 Control 122c 108e 96g 91i
Note. PTSDTOT = Davidson PTSD (Posttraumatic Stress Disorder) Scale; HAM–D = Hamilton Depression Scale; HIV symptoms = HIV symptom 
checklist.
a
Sample size given is for the PTSDTOT. For other variables, the sample size differs depending upon time point as follows:
b
HAM–D (N = 115), HIV symptoms (N = 121), CD4 (N = 118), and viral load (N = 118);
c
HIV symptoms (N = 123), CD4 (N = 121), and viral load (N = 121);
d
HAM–D (N = 103), HIV symptoms (N = 106), CD4 (N = 101), and viral load (N = 102);
e
CD4 (N = 107) and viral load (N = 105);
f
HAM–D (N = 95), HIV symptoms (>N = 93), CD4 (N = 95), and viral load (N = 96);
g
CD4 (N = 92) and viral load (N = 89);
h
HAM–D (N = 82), HIV symptoms (N = 81), CD4 (N = 78), and viral load (N = 81);
i
HAM–D (N = 89), HIV symptoms (N = 88), CD4 (N = 87), and viral load (N = 87).
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Table 4
Means and Standard Deviations (in Parentheses) for Main Study Outcomes (With A Significant Group by 
Gender Interaction) for Women and Men Separately Across Baseline and at 1-, 6-, and 12-Month Follow-Ups
Outcome Baseline 1 month 6 month 12 month
Women
 PTSDTOT
  Treatment 25.31 (25.93) 17.67 (19.75) 15.77 (20.23) 16.57 (17.33)
  Control 26.98 (22.98) 25.65 (23.22) 20.83 (23.30) 22.32 (26.35)
 HAM–D
  Treatment 9.56 (7.63) 6.88 (5.11) 6.56 (5.40) 7.08 (5.83)
  Control 9.92 (6.14) 9.00 (7.22) 9.61 (6.68) 8.05 (5.82)
 HIV symptoms
  Treatment 0.27 (0.45) 0.27 (0.45) 0.13 (0.34) 0.21 (0.41)
  Control 0.31 (0.47) 0.30 (0.47) 0.39 (0.49) 0.39 (0.50)
 Sample sizea
  Treatment 48b 43d 41e 38
  Control 47c 46 41 40f
Men
 PTSDTOT
  Treatment 29.28 (22.38) 22.72 (26.12) 19.13 (20.12) 19.39 (22.86)
  Control 29.69 (23.86) 22.50 (20.93) 19.09 (20.67) 14.41 (18.31)
 HAM–D
  Treatment 9.64 (5.44) 9.50 (6.81) 9.31 (6.97) 7.93 (6.62)
  Control 10.58 (7.25) 8.98 (7.36) 7.33 (6.43) 6.34 (5.29)
 HIV symptoms
  Treatment 0.23 (0.43) 0.21 (0.41) 0.25 (0.43) .23 (.43)
  Control 0.15 (0.36) 0.21 (0.41) 0.18 (0.39) .16 (.37)
 Sample sizea
  Treatment 72g 61i 53j 44k
  Control 75h 62 55 51l
Note. PTSDTOT = Davidson PTSD (Posttraumatic Stress Disorder) Scale; HAM–D = Hamilton Depression Scale; HIV symptoms = HIV symptom 
checklist.
a
Sample size is for PTSDTOT. For other variables, the sample size is as follows:
b
HAM–D (N = 45);
c
HAM–D (N = 48) and HIV symptoms (N = 48);
d
HIV symptoms (N = 44);
e
HIV symptoms (N = 40);
f
HAM–D (N = 39) and HIV symptoms (N = 38);
g
HAM–D (N = 70);
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h
HAM-D (N = 74);
i
HAM–D (N = 60);
j
HAM–D (N = 54);
k
HIV symptoms (N = 43);
l
HAM–D and HIV symptoms (N = 50).
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Table 5
Means and Standard Deviations (in Parentheses) for Main Study Outcomes for Women With Elevated PTSD 
Scores at Baseline (≥20) Across Baseline and 1-, 6-, and 12-Month Follow-Ups
Outcome Baseline 1 month 6 month 12 month
PTSDTOT
 Treatment 44.91 (23.13) 26.75 (21.20) 22.60 (23.49) 24.28 (19.89)
 Control 45.25 (19.07) 41.30 (22.94) 36.86 (24.94) 34.79 (30.60)
HAM–D
 Treatment 14.86 (7.51) 7.85 (4.36) 6.52 (5.60) 9.72 (6.07)
 Control 13.42 (5.56) 12.35 (7.27) 11.71 (5.97) 10.42 (6.07)
HIV symptoms
 Treatment 0.33 (0.48) 0.29 (0.46) 0.15 (0.37) 0.28 (0.46)
 Control 0.33 (0.48) 0.35 (0.49) 0.57 (0.51) 0.42 (0.51)
Sample sizea
 Treatment 24b 20c 21d 18
 Control 24 23 21 20e
Note. PTSDTOT = Davidson PTSD (Posttraumatic Stress Disorder) Scale; HAM–D = Hamilton Depression Scale; HIV symptoms = HIV symptom 
checklist.
a
Sample size given is for PTSDTOT. Where the sample size differs for other variables, the sample size is as follows:
b
HAM–D (N = 21);
c
HIV symptoms (N = 21);
d
HIV symptoms (N = 20);
e
HAM–D and HIV symptoms (N = 19).
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Table 6
Effect Sizes and 95% Confidence Intervals (in Brackets) for Symptoms of PTSD and Depression
PTSD Depression
Variable 6 months 12 months 6 months 12 months
All women
 Pre–post change trauma group 0.49 [0.18, 0.81] 0.45 [0.12, 0.78] 0.36 [0.04, 0.68] 0.37 [0.03, 0.70]
 Pre–post trauma vs. pre–post control 0.21 [−0.23, 0.65] 0.22 [−0.24, 0.67] 0.44 [0.00, 0.89] 0.25 [−0.20, 0.71]
Women with baseline PTSD score ≥20
 Pre–post change trauma group 1.12 [0.67, 1.57] 1.15 [0.66, 1.64] 0.89 [0.42, 1.37] 0.68 [0.16, 1.20]
 Pre–post trauma vs. pre–post control 0.63 [0.01, 1.26] 0.45 [−0.21, 1.11] 0.91 [0.26, 1.55] 0.47 [−0.22, 1.16]
All men
 Pre–post change trauma group 0.38 [0.10, 0.65] 0.42 [0.11, 0.72] 0.06 [−0.21, 0.34] 0.17 [−0.14, 0.48]
 Pre–post trauma vs. pre–post control −0.09 [−0.42, 0.30] −0.27 [−0.68, 0.14] −0.52 [−0.90, 0.13] −0.37 [−0.79, 0.05]
Entire sample
 Pre–post change trauma group 0.43 [0.23, .0.64] 0.44 [0.22, 0.66] 0.16 [−0.05, 0.37] 0.27 [0.05, 0.49]
 Pre–post trauma vs. pre–post control 0.04 [−0.25, .0.33] −0.06 [−0.36, 0.25] −0.05 [−0.33, 0.24] −0.09 [−0.39, 0.22]
Note. PTSD = Posttraumatic Stress Disorder.
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